Skip to main content
Figure 1 | Molecular Cancer

Figure 1

From: P-cadherin counteracts myosin II-B function: implications in melanoma progression

Figure 1

P-cadherin and myosin II-B expression in BLM LIE versus BLM P-cad. (A) Nonmuscle myosin heavy chain 10 (myosin II-B) mRNA was downregulated in BLM P-cad cells according to microarray analysis. Cadherin 3 (P-cadherin) mRNA levels were, as expected, upregulated in BLM P-cad. (B) Quantitative PCR validated the microarray data, indicating a 90% (± 5%) decrease in myosin II-B RNA expression in BLM P-cad and no P-cadherin RNA levels in BLM LIE. Error bars show the standard deviation for 2 independent experiments. (C) Decreased myosin II-B protein expression in BLM P-cad verifies microarray and PCR data. (D) Immunofluorescence staining of P-cadherin indicates the presence of functional P-cadherin mediated cell-cell contacts in BLM P-cad. (E) Western blot of myosin II isoforms in BLM LIE and P-cad. Equal amounts could be detected for myosin II-A, downregulation in BLM P-cad for myosin II-B, and no expression levels for myosin II-C. (scale bar = 25 μm)

Back to article page